Deka Biosciences

Executive Summary

Deka Biosciences, founded in 2020 and based in Germantown, Maryland, is a private biotechnology company pioneering a novel class of targeted cytokine therapies called Diakines. The platform combines specific cytokine pairs with proprietary targeting technology to concentrate therapeutic activity in diseased tissues, aiming to treat inflammatory diseases and cancer with high precision and reduced systemic toxicity. By enabling personalized immune modulation, Diakines have the potential to address significant unmet medical needs in indications where conventional cytokine therapies are limited by off-target effects and poor tolerability. The company is in the preclinical stage, advancing its lead Diakine candidates toward IND-enabling studies. While still early, Deks's platform could represent a differentiated approach in the increasingly competitive cytokine therapy space, particularly if it demonstrates superior efficacy and safety in animal models. Key near-term focus areas include finalizing IND filings for its lead programs in inflammation and oncology. The company's progress will depend on securing additional funding and potential partnerships to support clinical development. If successful, Diakines could become a new class of biologic drugs that more effectively harness the immune system for therapeutic benefit.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead Diakine Candidate40% success
• Q3 2026Series A or B Financing Round60% success
• Q3 2026Presentation of Preclinical Data at Major Conference70% success